Clinical Trial Update: Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for PAN-90806 eye drops in neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• PAN-90806

Snippet

Sponsor: PanOptica, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED